FDA Announces Request for Information Regarding the Quantitative Medicine Innovation Network
Today, the FDA Center for Drug Evaluation and Research (CDER), in partnership with the CDER Quantitative Medicine Center of Excellence, announced a request for information regarding a new collaborative ecosystem for quantitative medicine: the Quantitative Medicine Innovation Network (QMIN). QMIN is envisioned as a multi-stakeholder network to accelerate the translation of quantitative approaches across the drug discovery, development, regulation, and utilization continuum, fundamentally transforming how safe and effective therapies reach patients. This request for information is designed to gather input on how best to structure and implement QMIN to maximize its impact on public health.
FDA invites interested persons to provide detailed comments on the following topics: (1) identifying community needs and establishing mechanisms for continuous engagement; (2) supporting collaborative demonstration projects or research on innovative approaches aimed at addressing high priority areas through the application of QM approaches; and (3) exploring mechanisms to leverage community expertise and capacity to promote QM innovation and adoption.
Submit any comments regarding this notice to the public docket (Docket No. FDA-2026-N-7605) by November 3, 2026. Visit the Federal Register notice for additional information on how to comment.
The Office of Clinical Pharmacology (OCP) offers two e-mail subscription services, Clinical Pharmacology Corner and Quantitative Medicine, including Model-Informed Drug Development. These emails are a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events, and other items of interest. Subscribe today or click the button below and select Clinical Pharmacology Corner and Quantitative Medicine, including Model-Informed Drug Development under DRUGS.
We always welcome your thoughts regarding the format, content, and utility of our communications. Comments may be sent via email to ocp@fda.hhs.gov.
|
